Centogene N.V. (CNTG)
Market Cap | 34.39M |
Revenue (ttm) | 99.60M |
Net Income (ttm) | -52.57M |
Shares Out | 27.08M |
EPS (ttm) | -2.52 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 44,404 |
Open | 1.34 |
Previous Close | 1.29 |
Day's Range | 1.26 - 1.35 |
52-Week Range | 0.68 - 5.18 |
Beta | -1.08 |
Analysts | Buy |
Price Target | 2.55 (+100.79%) |
Earnings Date | Mar 28, 2023 |
About CNTG
Centogene N.V., together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide. It operates through three segments: Pharmaceutical, Diagnostics, and COVID-19 testing. The company develops rare disease platform, a data and biological repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide ... [Read more]
Financial Performance
In 2021, Centogene's revenue was 189.92 million, an increase of 47.94% compared to the previous year's 128.38 million. Losses were -46.41 million, 116.0% more than in 2020.
Financial numbers in EUR Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for CNTG stock is "Buy." The 12-month stock price forecast is $2.55, which is an increase of 100.79% from the latest price.
News

Twist Bioscience and CENTOGENE Launch Three Panels to Advance Rare Disease and Hereditary Cancer Research and Support Diagnostics
SOUTH SAN FRANCISCO, Calif. & CAMBRIDGE, Mass. & ROSTOCK, Germany & BERLIN--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering...

CENTOGENE and Denali Therapeutics Extend World's Largest Observational Study on Parkinson's Disease Genetics
Working together to deliver data-driven, informative genotyping answers to accelerate and de-risk drug discovery, development, and commercialization for Parkinson's disease (PD) Working together to de...

Premier Research and CENTOGENE Launch Strategic Partnership to Accelerate and De-Risk Rare Disease Clinical Development
Leveraging Rare Disease Insights Powered by the CENTOGENE Biodatabank and Centralized Multiomic Laboratories in Clinical Trials MORRISVILLE, N.C., and CAMBRIDGE, Mass.

CENTOGENE Announces Its Attendance at the 41st Annual J.P. Morgan Healthcare Meeting and Fierce JPM Week in San Francisco
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 28, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerat...

CENTOGENE Reports Second Quarter and First Half 2022 Financial Results
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerat...

CENTOGENE Receives Nasdaq Non-Compliance Notice
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 16, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerat...

CENTOGENE to Participate in Upcoming Conferences in December
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerat...

CENTOGENE Announces Changes to Supervisory Board, Including Appointment of Mary Sheahan
Adding significant financial expertise with an impressive track record in value creation Adding significant financial expertise with an impressive track record in value creation

CENTOGENE to Participate in Upcoming Conferences in November
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerat...

CENTOGENE Launches Rare and Neurodegenerative Disease Biodata Network
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerat...

CENTOGENE to Participate in Upcoming Partnering Conferences in October
CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the commercial-stage essential biodata life science partner for rare and neurodegene...

CENTOGENE Reaches 12,500 Patient Milestone in World's Largest Observational Study on Parkinson's Disease Genetics
Working together with Denali Therapeutics to accelerate data-driven precision medicine for the PD community

CENTOGENE to Present at Upcoming Investor & Partnering Conferences in September
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the commercial-stage essential biodata life science partner for rare and neurodegene...

CENTOGENE Reports First Quarter 2022 Financial Results
On Track for FY 2022 Guidance

CENTOGENE Announces Shareholder Approval of All Resolutions at 2022 Annual General Meeting
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 27, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the commercial-stage, essential biodata life science partner for rare and neurodegene...

CENTOGENE Announces Appointment of Miguel Coego Rios as Chief Financial Officer
Interim CFO Miguel Coego Rios appointed as Managing Director and permanent CFO Interim CFO Miguel Coego Rios appointed as Managing Director and permanent CFO

CENTOGENE and Agios Expand Partnership for Clinical Development of PYRUKYND® (mitapivat) to Treat Children With Rare Blood Disease
Working together on the world's first treatment that targets the underlying causes of pyruvate kinase (“PK”) deficiency in children under the age of 18 Working together on the world's first treatment ...

CENTOGENE's CentoCloud® Is Now CE-Marked as One of the Only Decentralized SaaS Platforms Compliant With European IVD Regulatory Framework
CE-marked clinical decision support platform enables laboratories to provide best-in-class diagnostics of genetic diseases CE-marked clinical decision support platform enables laboratories to provide ...

CENTOGENE Contributes to Europe-Wide Efforts to Update Guidelines for Whole Genome Sequencing (WGS) in Rare Disease Diagnostics
Newly established WGS recommendations published in the European Journal of Human Genetics

CENTOGENE to Present at the H.C. Wainwright Global Investment Conference
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 19, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the commercial-stage essential biodata life science partner for rare and neurodegenera...

CENTOGENE and Takeda Extend Market Access and Expansion Partnership to Advance Patient Care Globally
Accelerating the path from diagnosis to available treatments for rare metabolic and rare neurodegenerative diseases

CENTOGENE Reports Fourth Quarter and Full Year 2021 Financial Results
- Full Year 2021 Total Revenue Growth of 48%, and 11% in Core Business Segments, Exceeds Guidance

CENTOGENE CEO Kim Stratton to Speak at BIO-Europe Spring® 2022 Conference
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 24, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, u...

CENTOGENE to Announce Fourth Quarter and Fiscal Year 2021 Financial Results on March 30, 2022
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 23, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, u...

CENTOGENE Announces Expansion of Data Access and Collaboration Agreement With Pfizer
ROSTOCK, Germany and BERLIN, March 17, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat ...